Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Bylaw Amendment (Apr 24, 2026)

Reports
Corporate Changes·Exhibits & Filings
Filing Date
Filed April 24, 2026
Period End
April 22, 2026
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Nov ’19Nov ’19
  3. Leadership change8-K · Feb ’23Feb ’23
  4. Leadership change8-K · Mar ’25Mar ’25

Summary

Summary of the 8-K filed April 24, 2026. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. filed a Current Report on Form 8-K on April 24, 2026 to disclose amendments to its Bylaws adopted by the Board of Directors on April 22, 2026.

The filing does not report financial results, financial figures, or operating developments. The first amendment revises Section 2.5 of the Bylaws to provide that directors may be removed from office at any time, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of the directors.

The second amendment revises Section 1.12 to clarify that any action required or permitted to be taken at an annual or special meeting of stockholders may not be taken without a meeting, consistent with Article FIFTH of the Certificate of Incorporation. The full amended Bylaws are filed as Exhibit 3.1, and the filing includes the Cover Page Interactive Data File (Exhibit 104) formatted as inline XBRL.

Key Highlights

  1. Board amended Bylaws on April 22, 2026, with the 8-K filed April 24, 2026.
  2. Section 2.5 revised so directors may be removed at any time, with or without cause, by a majority of shares entitled to vote in director elections.
  3. Section 1.12 clarified that stockholder actions at annual or special meetings may not be taken without a meeting, consistent with Article FIFTH of the Certificate of Incorporation.
  4. The removal provision change relates to director accountability and board composition rules for stockholders.
  5. The filing reports no financial results, financial figures, or operating updates.
  6. Full amended Bylaws are filed as Exhibit 3.1.

Frequently Asked Questions

  1. What changed in Halozyme's Bylaws?

    The Board amended Section 2.5 to allow directors to be removed at any time, with or without cause, by a majority of shares then entitled to vote in director elections. It also revised Section 1.12 to clarify that stockholder actions at annual or special meetings may not be taken without a meeting, consistent with Article FIFTH of the Certificate of Incorporation.

  2. When were the Bylaw amendments adopted?

    The Board of Directors adopted the amendments on April 22, 2026, and the Company reported them in an 8-K filed April 24, 2026.

  3. Does this filing include financial results?

    No. The filing covers only the Bylaw amendments under Item 5.03 and lists the amended Bylaws (Exhibit 3.1) and the XBRL cover page (Exhibit 104) as exhibits.

  4. Where can investors find the full text of the amended Bylaws?

    The complete amended Bylaws are attached to the filing as Exhibit 3.1 and incorporated by reference into the 8-K.